PSD502 in Subjects With Premature Ejaculation

PHASE2CompletedINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

December 26, 2018

Primary Completion Date

May 4, 2021

Study Completion Date

December 1, 2021

Conditions
Premature Ejaculation
Interventions
DRUG

Placebo

"For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing."

DRUG

PSD502

"For each sexual encounter during the 4-week treatment period the study spray will be applied 5 minutes before intercourse and any excess will be wiped off prior to penetration.~Study subjects should leave at least 24 hours between each dosing."

Trial Locations (21)

10016

Manhattan Medical Research Practice, New York

11530

Accumed Research Associates, Garden City

12601

Premier Medical Group of the Hudson Valley, Poughkeepsie

19004

Midlantic Urology, Bala-Cynwyd

21204

Chesapeake Urology Research Associates, Towson

27612

M3 Wake Research, Inc, Raleigh

30044

Georgia Clinical Research, Llc, Lawrenceville

30312

Primary Care Research, Atlanta

33014

Suncoast Research Associates, Miami Lakes

33060

Clinical Research Center of Florida, Pompano Beach

33133

SunCoast Research, Miami

33435

Imagine Research of Palm Beach County, Boynton Beach

35216

Achieve Clinical Research, Birmingham

36608

Coastal Clinical Research, Mobile

71106

Regional Urology, LLC, Shreveport

84088

Advanced Clinical Research, West Jordan

84123

Advanced Clinical Research - Jordan Ridge Family Medicine, Salt Lake City

89106

Jubilee Clinical Research, Inc, Las Vegas

91411

Skyline Urology, Sherman Oaks

02131

Boston Clinical Trials, Boston

02467

Mens Health Boston, Chestnut Hill

Sponsors
All Listed Sponsors
lead

Plethora Solutions Ltd

INDUSTRY

NCT03578783 - PSD502 in Subjects With Premature Ejaculation | Biotech Hunter | Biotech Hunter